Earnings ·
Integra LifeSciences Holdings Corporation announced preliminary unaudited results for the third quarter ended…
IARTIntegra Lifesciences Holdings Corp
Integra LifeSciences Holdings Corporation announced preliminary unaudited results for the third quarter ended September 30, 2026, and updated its full-year guidance. The company expects Q3 revenue of $410 million to $412 million and adjusted diluted EPS of $0.55 to $0.59, reflecting a $7 million negative impact from flooding-related supply disruptions at its Cincinnati manufacturing facility. Full-year 2026 reported revenue guidance was lowered to $1.634 billion–$1.654 billion (from $1.654 billion–$1.695 billion), and adjusted diluted EPS guidance was reduced to $2.30–$2.40 (from $2.40–$2.50). The company anticipates Q3 operating cash flow exceeding $85 million and full-year operating cash flow of approximately $190 million to $200 million. Integra expects a return to full manufacturing operations at the Cincinnati facility in the second quarter of 2027, with insurance recoveries expected to mitigate a substantial portion of the earnings impact. Integra LifeSciences is a global medical technology company specializing in neurosurgery and tissue reconstruction products.